FDA Approves Dupixent as First and Only Targeted Therapy for Bullous Pemphigoid in the US
FDA Approves Dupixent as the First and Only Targeted Therapy for Adults with Bullous Pemphigoid In a groundbreaking development for patients suffering from a rare and debilitating autoimmune skin disease,…
Combination of Lunsumio and Polivy from Roche Significantly Extends Remission in R/R Large B-Cell Lymphoma
Roche’s Lunsumio and Polivy Combination Marks Major Advance in Relapsed or Refractory Large B-Cell Lymphoma with Significant Remission Durability Roche has announced promising results from its pivotal Phase III SUNMO…
H20 Summit to Shape G20 Health Agenda and Financing
Rebuilding Trust and Reshaping Global Health Finance: H20 Summit Lays Groundwork for G20 Health Agenda From June 19 to 20, global leaders in health and development converged in Geneva for…
Civil Society Drives Global Health Agenda at WHA78
Civil Society Deepens Its Role in Shaping Global Health Policy at WHA78 At the 78th World Health Assembly (WHA78), held under the unifying theme “One World for Health,” a pivotal…
Grifols’ Fibrinogen Phase 3 Results Published in eClinicalMedicine
Grifols’ BT524 Fibrinogen Therapy Shows Promise in Phase 3 Trial Published in The Lancet’s eClinicalMedicine Grifols, a globally recognized healthcare company and a leader in the production of plasma-derived therapies,…
Alnylam Promotes Pushkal Garg to Chief R&D Officer
Alnylam Elevates Dr. Pushkal Garg to Lead Unified Research and Development Organization, Signaling Strategic Expansion into Next Phase of RNAi Therapeutics Innovation Alnylam Pharmaceuticals, a global leader in RNA interference…
Biogen Launches Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia
Biogen Launches Global Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia Biogen has officially launched its BRAVE study a pivotal, global Phase 3 clinical trial aimed at evaluating omaveloxolone…
Merck Names Neoclease Winner of 2025 Biotech Grant
Merck Awards 2025 North American Advance Biotech Grant to Neoclease for AI-Driven Parkinson’s Gene Editing Therapy Merck, a global leader in science and technology, has officially named Neoclease as the…
Amgen to Present Phase 2 Maritide Data at ADA 85th Scientific Sessions
Amgen to Unveil Full Phase 2 MariTide Data and Cardiometabolic Research Highlights at ADA 2025 Scientific Sessions Amgen has announced that it will present comprehensive data from Part 1 of…
Phase 3 Trial of Ifinatamab Deruxtecan Begins in Advanced Prostate Cancer
Phase 3 Trial Launches for Ifinatamab Deruxtecan in Advanced Prostate Cancer Patients Daiichi Sankyo and Merck have announced the initiation of IDeate-Prostate01, a global Phase 3 clinical trial evaluating the…
AbbVie: Atogepant Outperforms Topiramate in Phase 3 Migraine Study
AbbVie Reports Strong Phase 3 Results for Atogepant, Demonstrating Superiority Over Topiramate in Migraine Prevention AbbVie, a leading global biopharmaceutical company, has announced promising topline results from its pivotal Phase…
Teva and Fosun Partner to Develop Novel Anti-PD1-IL2 Immunotherapy
Teva and Fosun Pharma Forge Strategic Partnership to Develop and Commercialize Innovative Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva Pharmaceutical Industries Ltd.and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.today announced a significant…